Isomab Welcomes Professor Bill Sessa as Chair of its Scientific Advisory Board
Isomab Welcomes Professor Bill Sessa to Lead Scientific Advisory Board
In a significant move for the biotechnology field, Isomab Ltd, a UK-based company specializing in innovative therapies for cardiovascular diseases, has announced the appointment of Professor Bill Sessa as Chair of its Scientific Advisory Board (SAB). Professor Sessa, known for his extensive work in internal medicine and vascular biology, brings a wealth of experience, having previously served as the Chief Scientific Officer of Internal Medicine at Pfizer.
Advancing Cardiovascular Health
Isomab is at the forefront of developing novel therapies aimed at restoring vascularization, particularly through its lead program ISM-001. This first-in-class monoclonal antibody targets VEGF-A165b, focusing on conditions like chronic angina that are often resistant to existing standard-of-care interventions. Professor Sessa's leadership in this initiative is anticipated to significantly bolster Isomab’s research and development efforts.
“VEGF-A165b antagonism represents a genuinely novel approach to restoring vascularization in ischaemic disease,” remarked Professor Sessa. His enthusiasm for guiding Isomab's mission reflects his deep-seated commitment to addressing unmet medical needs in vascular health.
A Distinguished Advisory Panel
Joining Professor Sessa on the SAB is a formidable group of leading vascular biologists and medical experts from prestigious institutions such as Yale, Harvard, Uppsala University, and the University of Eastern Finland. Among them is Professor Tim Hla, who is recognized for his groundbreaking work on the COX-2 pathway and S1P receptors. Also on the board is Professor Lena Claesson-Welsh, an authority on VEGFR2 signal transduction, and Professor Seppo Ylä-Herttuala, a pioneer in cardiovascular gene therapy.
Under Professor Sessa’s guidance and the SAB’s expertise, Isomab is poised to complete a critical clinical biomarker study and enhance its preclinical development as it moves towards human clinical trials. This foundational approach has the potential to not only advance Isomab's scientific endeavors but also to redefine treatment options for patients suffering from chronic angina and other ischemic conditions.
Looking Ahead
Philip Brainin, CEO of Isomab, emphasized the significance of this appointment, stating, “As we advance ISM-001 toward the clinic, having Bill and this board rigorously challenge our mechanistic narrative and preclinical package is an enormous asset to the Company and ultimately to patients with cardiovascular disease.” This collaborative effort underlines Isomab's dedication to pioneering innovative therapies that can improve patient outcomes.
Isomab Ltd continues to expand its mission with a focus on developing antibody therapies that aim for significant advancements in cardiovascular care, and with the esteemed Professor Bill Sessa steering the Scientific Advisory Board, the company’s future initiatives hold great promise.
Contact Information
For further information on Isomab and its programs, visit www.isomab.bio.
Stay tuned for updates on the developments and breakthroughs from Isomab as they work towards bringing their transformative therapies to market.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.